Peeters F, Dekervel J. Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma. Curr Opin Pharmacol. 2023;70: 102365.

Article  CAS  PubMed  Google Scholar 

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol [Internet]. 2022 [cited 2023 Jul 19];77:1598–606. Available from: http://www.journal-of-hepatology.eu/article/S0168827822030227/fulltext.

Liver cancer survival rates | Cancer of the liver survival rates | American Cancer Society [Internet]. [cited 2023 Jul 19]. Available from: https://www.cancer.org/cancer/types/liver-cancer/detection-diagnosis-staging/survival-rates.html.

Suresh D, Srinivas AN, Prashant A, Harikumar KB, Kumar DP. Therapeutic options in hepatocellular carcinoma: a comprehensive review. Clin Exp Med. 2023

Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2018;48:103–14.

Article  PubMed  Google Scholar 

Sharma A, Houshyar R, Bhosale P, Choi J-I, Gulati R, Lall C. Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol. 2014;20:317.

Article  PubMed  PubMed Central  Google Scholar 

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769–92.

Article  PubMed  Google Scholar 

Definition of metronomic chemotherapy - NCI Dictionary of Cancer Terms - NCI [Internet]. [cited 2023 Apr 12]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/metronomic-chemotherapy.

Maiti R. Metronomic chemotherapy J Pharmacol Pharmacother. 2014;5:186–92.

Article  CAS  PubMed  Google Scholar 

Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. The Indian Journal of Pediatrics. 2012;79:1617–22.

Article  PubMed  Google Scholar 

Cazzaniga ME, Cordani N, Capici S, Cogliati V, Riva F, Cerrito MG. Metronomic chemotherapy. Cancers (Basel). 2021;13:2236.

Article  CAS  PubMed  Google Scholar 

Simsek C, Esin E, Yalcin S. Metronomic chemotherapy: a systematic review of the literature and clinical experience. J Oncol. 2019;2019:1–31.

Article  Google Scholar 

Knikman JE, Rosing H, Guchelaar H, Cats A, Beijnen JH. A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. Biomed. Chromatogr. 2020;34. https://doi.org/10.1002/bmc.4732.

Xeloda | European Medicines Agency [Internet]. [cited 2023 Jul 25]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda.

Liu J, He M, Wang Z, Li Q, Xu B. Current research status of metronomic chemotherapy in combination treatment of breast cancer. Oncol Res Treat. 2022;45:681–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, He M, Liu J, Wang Z. Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: a phase II trial. J Clin Oncol. 2023;41:e13038–e13038.

Article  Google Scholar 

El-Sukhun S, Khalidi K. Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma. Ecancermedicalscience. 2023;17.

Wang-Yuan Z, Jiang-Zheng Z, Lu Y Da, Hao XB, Hong T, Huang F, et al. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma. International Journal of Hyperthermia [Internet]. 2016;32:193–8. Available from: https://doi.org/10.3109/02656736.2015.1099168.

Granito A, Marinelli S, Terzi E, Piscaglia F, Renzulli M, Venerandi L, et al. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Digestive and Liver Disease [Internet]. 2015;47:518–22. Available from: https://doi.org/10.1016/j.dld.2015.03.010.

De Lorenzo S, Tovoli F, Barbera MA, Garuti F, Palloni A, Frega G, et al. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. Scientific Reports (Nature Publisher Group) [Internet]. 2018;8:1–7. Available from: https://www.proquest.com/scholarly-journals/metronomic-capecitabine-vs-best-supportive-care/docview/2063690119/se-2.

Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, et al. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Scientific Reports (Nature Publisher Group) [Internet]. 2017;7:42499. Available from: https://www.proquest.com/scholarly-journals/metronomic-capecitabine-versus-best-supportive/docview/1901710928/se-2?accountid=211620.

Brandi G, Rosa F, Agostini V, Girolamo S, Andreone P, Bolondi L, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist [Internet]. 2013;18:1256–7. Available from: https://doi.org/10.1634/theoncologist.2013-0093.

Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Cancers (Basel) [Internet]. 2021;13:4882. Available from: https://www.proquest.com/scholarly-journals/management-hepatocellular-carcinoma-recurrence/docview/2580978526/se-2.

Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol [Internet]. 2018;144:403–14. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038115440&doi=10.1007%2fs00432-017-2556-6&partnerID=40&md5=bb5c4194808707f315f0a710419ac725.

Ravaioli M, Cucchetti A, Pinna AD, De Pace V, Neri F, Barbera MA, et al. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. Scientific Reports (Nature Publisher Group) [Internet]. 2017;7:1–9. Available from: https://www.proquest.com/scholarly-journals/role-metronomic-capecitabine-treatment-recurrent/docview/1954329902/se-2.

Peristeri DV, Tepelenis K, Karampa A, Kapodistrias N, Goussia AC, Pappas-Gogos G, et al. Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: a case report. Ann Med Surg (Lond). 2021;72: 103043.

Article  PubMed  Google Scholar 

Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, et al. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol. 2013;6:511–9.

Article  PubMed  PubMed Central  Google Scholar 

Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, et al. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017;23:128–37.

Article  PubMed  PubMed Central  Google Scholar 

Banchi M, Lanzolla T, Di Napoli A, Bandini A, Bocci G, Cox MC. Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib: a case report. Chemotherapy. 2023;

Marinelli S, Granito A, Piscaglia F, Renzulli M, Stagni A, Bolondi L. Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. Hepat Mon. 2013;13.

Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol. 2010;17:3137–44.

Article  PubMed  Google Scholar 

Mireștean CC, Iancu RI, Iancu DPT. Capecitabine-a “permanent mission” in head and neck cancers “war council”? J Clin Med. 2022;11.

Schellens JHM. Capecitabine Oncologist. 2007;12:152–5.

Article  CAS  PubMed  Google Scholar 

Zafar SY, Hirsch. Capecitabine in the management of colorectal cancer. Cancer Manag Res. 2011;79.

Albarrak J, Al-Shamsi H. Current status of management of hepatocellular carcinoma in the Gulf region: challenges and recommendations. Cancers (Basel). 2023;15:2001.

Article  CAS  PubMed  Google Scholar 

Jan N, Sofi S, Qayoom H, Shabir A, Haq BU, Macha MA, et al. Metronomic chemotherapy and drug repurposing: a paradigm shift in oncology. Heliyon. 2024;10: e24670.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geng R, Wang G, Qiu L, Liu B, Yang F, Zhang J, et al. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients. Medicine. 2020;99: e23719.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer. 2014;14:184.

Article  PubMed  PubMed Central  Google Scholar 

Ibrahim T, Bongiovanni A, Riva N, Ricci M, Calpona S, Gunelli E, et al. Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature. Onco Targets Ther. 2014;1919.

Fedele P, Marino A, Orlando L, Schiavone P, Nacci A, Sponziello F, et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer. 2012;48:24–9.

Article  CAS  PubMed  Google Scholar 

Yuan Z, Hua X, Li W-Z, Huang H, Cai L, Lin Y, et al. Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: results from the SYSUCC-001 study. J Clin Oncol. 2021;39:521–521.

Article  Google Scholar 

Liu Y, Gu F, Liang J, Dai X, Wan C, Hong X, et al. The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: a meta-analysis. PLoS ONE. 2017;12: e0173693.

Article  PubMed  PubMed Central  Google Scholar 

He S, Shen J, Hong L, Niu L, Niu D. Capecitabine, “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol. 2012;29:100–6.

Article  CAS  PubMed  Google Scholar 

Raimondi A, Corallo S, Niger M, Antista M, Randon G, Morano F, et al. Metronomic capecitabine with cyclophosphamide regimen in unresectable or relapsed Pseudomyxoma peritonei. Clin Colorectal Cancer. 2019;18:e179–90.

Article  PubMed  Google Scholar 

Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785–94.

Article  PubMed  Google Scholar 

Mathur MB, VanderWeele TJ. Sensitivity analysis for publication bias in meta-analyses. J R Stat Soc Ser C Appl Stat. 2020;69:1091–119.

Article  PubMed  PubMed Central  Google Scholar 

Qin L-X. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol. 2002;8:385.